Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract s ...

Core Insights - RenovoRx has established a Medical Advisory Board (MAB) to enhance its TAMP™ therapy platform, focusing on clinical indications with high unmet medical needs [1][2][5] Group 1: Medical Advisory Board Formation - The MAB consists of leading US interventional radiology experts who will provide strategic clinical insights to advance the TAMP therapy platform [2][3] - The MAB will complement the existing Scientific Advisory Board, which focuses on scientific research and clinical program strategy [2] Group 2: Clinical and Market Strategy - The MAB will support ongoing clinical and market strategies and provide insights into potential investigator-initiated trials, which are designed to broaden the application of the TAMP platform [3] - Current trials supported by RenovoRx include studies on borderline resectable and metastatic pancreatic cancer, with potential for expanding targeted indications [3] Group 3: Feedback and Market Introduction - The MAB will also provide feedback to the sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications [4] Group 4: RenovoCath Overview - RenovoCath is an FDA-cleared drug-delivery device intended for targeted therapeutic delivery across the arterial wall near tumor sites, aiming to minimize toxicities compared to systemic intravenous therapy [12][13] - The device is also indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [12] Group 5: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices, generating approximately $900,000 in revenue for the first nine months of 2025 [14] - The company is actively exploring further revenue-generating activities to meet anticipated demand [14] Group 6: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [15][16] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [17]

Core Insights - RenovoRx, Inc. is advancing its innovative targeted oncology therapies through the RenovoCath device, which has received FDA clearance for drug delivery [1][7] - New clinical data will be presented at the 2026 Society of Interventional Oncology Annual Scientific Meeting, focusing on optimizing drug delivery in solid tumors using the TAMP therapy platform [1][2] Clinical Study Findings - The study titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" aims to simplify intra-arterial pressure measurement during TAMP procedures [2][4] - Real-time pressure measurements provide insights into the mechanics of TAMP procedures, potentially enhancing drug delivery effectiveness [3][4] - The study demonstrates that an external pressure transducer can reliably measure intra-arterial pressure, correlating well with intravascular pressure wire measurements [3] Presentation Details - The clinical data will be presented on February 6, 2026, at 5:45-6:00 PM ET, with the abstract number 303 [4] Company Overview - RenovoRx is focused on developing targeted therapies for high unmet medical needs, utilizing the TAMP therapy platform to minimize toxicities compared to systemic therapies [7] - The company is in the early stages of commercializing the RenovoCath device, having generated approximately $900,000 in revenue from sales in the first nine months of 2025 [8] Product Development - RenovoRx is evaluating a novel drug-device combination candidate, IAG, which involves intra-arterial delivery of gemcitabine via RenovoCath, currently in Phase III trials [9][10] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [10]